WALTHAM, Mass.--(BUSINESS WIRE)--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that interim results from an ongoing Phase Ib study of its lead product candidate, ZYBRESTAT™ (combretastatin-A4 phosphate / CA4P), administered in combination with bevacizumab (AVASTIN®) to patients with advanced solid tumors, were presented today at the European School of Haematology’s International Conference on Vascular Targeted Therapies in Oncology in Mandelieu, France.
